Thrombotic Thrombocytopenic Purpura and Haemolytic Uraemic Syndrome (Congenital and Acquired)

Postgraduate Haematology: Fifth Edition

Volumn , Issue , 2007, Pages 876-884

  Mannucci, Pier M ^a   Peyvandi, Flora ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Atypical (non diarrhoea related) haemolytic uraemic syndrome; Familial haemolytic uraemic syndrome; Haemolytic uraemic syndrome (HUS); Plasma therapy; Thrombotic thrombocytopenic purpura (TTP)

Indexed keywords

EID: 79851501355     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470987056.ch52     Document Type: Chapter

References (18)

1. Bell WR, Braine HG, Ness PM et al. (1991) Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Clinical experience in 108 patients. New England Journal of Medicine 325: 398-403.
2. Bukowski RM, King JW, Hewlett JS (1977) Plasmapheresis in the treatment of thrombotic thrombocytopenic purpura. Blood 50: 413-17.
3. Furlan M, Robles R, Galbusera M et al. (1998) von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. New England Journal of Medicine 339: 1578-84.
4. Gorge JN (2000) How I treat patients with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Blood 96: 1223-9.
5. Levy GG, Nichols WC, Lian EC et al. (2001) Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 413: 488-94.
6. Mannucci PM, Lombardi R, Lattuada A et al. (1989) Enhanced proteolysis of plasma von Willebrand factor in thrombotic thrombocytopenic purpura and the hemolytic uremic syndrome. Blood 74: 978-83.
7. Mannucci PM, Canciani MT, Forza I et al. (2001) Changes in health and disease of the metalloprotease that cleaves von Willebrand factor. Blood 98: 2730-5.
8. Manuelian T, Hellwage J, Meri S et al. (2003) Mutations in factor H reduce binding affinity to C3b and heparin and surface attachment to endothelial cells in hemolytic uremic syndrome. Journal of Clinical Investment 111: 1181-90.
9. Moake J (1998) Moschcowitz, multimers, and metalloprotease. New England Journal of Medicine 339: 1629-31.
10. Moake JL (2002) Thrombotic microangiopathies. New England Journal of Medicine 347: 589-600.
11. Moake JL, Rudy CK, Troll JH et al. (1982) Unusually large plasma factor VIII: von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura. New England Journal of Medicine 307: 1432-5.
12. Moake JL, Turner NA, Stathopoulos NA et al. (1986) Involvement of large plasma von Willebrand factor (vWF) multimers and unusually large vWF forms derived from endothelial cells in shear stress-induced platelet aggregation. Journal of Clinical Investment 78: 1456-61.
13. Moore JB, Hayward CPM, Warkentin TE et al. (2001) Decreased von Willebrand factor protease activity associated with thrombocytopenic disorders. Blood 98: 1842-6.
14. Remuzzi G, Ruggenenti P, Bertani T (1994) Thrombotic microangiopathy. In Renal Pathology (CC Tisher, MM Brenner, eds), 2nd edn, p. 1154. Lippincott, Philadelphia.
15. Remuzzi G, Galbusera M, Noris M et al. (2002) Thrombotic thrombocytopenic purpura/hemolytic uremic syndrome: von Willebrand factor cleaving protease (ADAMTS13) is deficient in recurrent and familial thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. Blood 100: 778-85. 883
16. Postgraduate Haematology Upshwas JD (1978) Congenital deficiency of a factor in normal plasma that reverses microangiopathic hemolysis and thrombocytopenia. New England Journal of Medicine 298: 1350-2.
17. Vesely SK, George JN, Lammle B et al. (2003) ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome:relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. Blood 102: 60-8.
18. Zheng X, Chung D, Takayama TK et al. (2001) Structure of von Willebrand factor-cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura. Journal of Biological Chemistry 276: 41059-63.